Last session pushed beyond bacteria. Azole-resistant Aspergillus linked to agricultural fungicides. C. auris likely accelerated by climate change. Almost no global capacity for fungal genomic surveillance. AMR is bigger than bacteria. www.amrsurveillance.org
#AMRSurveillanceAddis
Four national stories. Philippines: 38 years of AMR surveillance, now adding WGS. Uganda: 16 to 43 sites. Pakistan: building a genomic strategy. Brazil: mapping labs nationally. Start small, invest in quality, build government ownership. #AMRSurveillanceAddis
Day 1 of www.amrsurveillance.org
Sentinel site session was the most grounding. Surveillance fails when it's extractive — data goes up, nothing comes back. Labs engage when it improves their own practice. www.amrsurveillance.org
#AMRSurveillanceAddis
Reporting from the AMR Surveillance Convening at Africa CDC, Addis Ababa. Opening message was direct: the surveillance gap isn't about knowledge anymore, it's delivery and financing. Africa carries ~21% of the global AMR burden.
Recap of Day 1 from www.amrsurveillance.org
#AMRSurveillanceAddis
Nearly 90% of AMR pathogen genomes come from high-income countries.109 participants from 52 countries meeting in Addis Ababa to close this gap. www.amrsurveillance.org
#AMR #HealthEquity #Genomics #AMRSurveillanceAddis
From pilots to practice - translating ambition into stronger, more effective surveillance systems that protect public health globally.
#AMR #AntimicrobialResistance #Genomics #GlobalHealth #PublicHealth #AMRSurveillanceAddis
See more at: www.amrsurveillance.org
In support of the UN General Assembly commitment to reduce AMR-related deaths by 10% by 2030, the meeting is centred on learning from real-world experience, identifying common challenges across diverse settings, and agreeing on practical next steps for nationally owned AMR surveillance.
Organised by Africa CDC, @thecgps.bsky.social , the Fleming Initiative, and the International Vaccine Institute, the convening brings together ministry and public health laboratory leads, regional networks, researchers, and global partners.
109 participants from 52 countries are convening at Africa CDC Headquarters in Addis Ababa for a focused, experience-led meeting on strengthening routine national antimicrobial resistance (AMR) surveillance systems, including the integration of pathogen genomic data.
More at www.amrsurveillance.org
Organised by Africa CDC, the Centre for Genomic Pathogen Surveillance, the Fleming Initiative, and the International Vaccine Institute, the convening brings together ministry and public health laboratory leads, regional networks, researchers, and global partners.
Future planned updates include a) incorporation and filtering of additional metadata (e.g. isolate source), b) adding the ability to display data from bespoke genome collections (including user-defined) and c) extending to additional pathogens/vaccine targets.
vaccines.watch currently displays data for >100k high-quality genomes with geotemporal sampling information (post-2010), but we demonstrate that substantial biases and geographic gaps remain in the coverage of available genomes.
With analytics powered by Pathogenwatch (pathogen.watch), the platform uses the same “always-on” pipeline as the sister tool, amr.watch (amr.watch), with new genomes assembled, analysed and incorporated on an ongoing basis (every 4h) as public data are newly deposited.
The interactive interface enables users to assess vaccine target types (e.g. serotypes) within a broader population context by enabling assessment of their relationships with associated variant types (e.g. STs) and AMR markers, and within the context of existing pneumococcal vaccine formulations.
We’ve initially focused on showing data for existing/prospective multivalent polysaccharide-based vaccines for Streptococcus pneumoniae, Klebsiella pneumoniae (and related species) and Acinetobacter baumannii.
As global representativeness of data grows from increased genomic surveillance, we have designed vaccines.watch to support different stages of the vaccine pipeline, although caution in interpretation is currently important due to data representativeness (see below).
Pleased to share our latest preprint describing vaccines.watch (vaccines.watch), an interactive platform enabling exploration of vaccine target diversity from global genome data: www.biorxiv.org/content/10.1...
By combining survey data with additional public data, we also found substantial global spread of high-risk E. coli clones (e.g. ST167) with NDM-5 and other carbapenemases. We found many introductions of these clones into European hospitals in 2019, albeit with limited onward nosocomial transmission.
Our findings suggest that the situation with carbapenem-resistant K. pneumoniae has continued to worsen and that control measures have not been able to interrupt transmission of high-risk lineages circulating within European hospital networks.
Special thanks also to the project leads and collaborators @ecdc.europa.eu and Public Health Agency of Sweden, especially Anke Kohlenberg, Alma Brolund and Inga Froding, with whom it has been a pleasure to work with and learn from over the many years spanning the project.
The work comes together from the valiant efforts of all participating hospitals and national reference laboratories, forming the EURGen-Net CCRE Survey Working Group, who were able to continue with the data collection even despite onset of the COVID-19 pandemic shortly after the survey period.
The manuscripts, which follow up on the 2013-14 EuSCAPE survey, describe the occurrence and spread of carbapenem-resistant K. pneumoniae and E. coli using epidemiological, microbiological and WGS data obtained for isolates from >300 hospitals.
We’re pleased to share two new preprints with results from a structured survey of carbapenem- and/or colistin-resistant Enterobacterales (CCRE), conducted in 37 European countries in 2019.
E. coli: papers.ssrn.com/sol3/papers....
K. pneumoniae: papers.ssrn.com/sol3/papers....
amr.watch can be used to assess representation of geographic regions, e.g. with countries here in white currently lacking any public genomes. See more at amr.watch/all (6/6)
Huge disparity in genomic data. We support all efforts to increase the genomic surveillance of pathogens on a global scale as dynamics differ locally - what happens in one place does not translate to another and high-risk clones can emerge anywhere. (5/6)
Always on: all QC-d genomes with geotemporal metadata are ingested from archives, analysed in pathogen.watch and results visualised in amr.watch. Data are extracted and updated every 4h, with observed trends thus only delayed by time to genome deposition. More on filtering: amr.watch/summary (4/6)
We show disparities between high- and low-income settings, indicate vast gaps in our knowledge globally and highlight the need for ongoing, structured surveillance combined with timely data deposition (including metadata) to support public health. (3/6)
Supporting all WHO priority pathogens (2017), amr.watch summarises the geographic and temporal distribution of genotypic variants (e.g. STs) in the context of AMR to aid monitoring and prioritisation efforts. (2/6)
Our latest preprint is out describing amr.watch - a platform for monitoring AMR trends from global genomics data: www.biorxiv.org/content/10.1... (1/6)
We’ve just released a public Pathogenwatch collection of the MRSN Diversity Panel comprising 100 diverse K. pneumoniae clinical isolates: pathogen.watch/collection/8... #KlebClub